Table 2.
The comparisons between pre-treatment and post-treatment serum Alanine aminotransferase (ALT) and IFN-γ-inducible protein-10 (IP-10) levels were conducted in chronic hepatitis B (CHB) patients
| Group | Case | ALT (U/L) | IP-10 (pg/mL) | ||
|---|---|---|---|---|---|
|
| |||||
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | ||
| Control group | 25 | 32.8 ± 3.5 | 78.1 ± 33.8 | ||
| CHB group | 57 | 40.6 ± 5.2 | 33.1 ± 3.9* | 285.7 ± 41.6 | 78.5 ± 20.4* |
| HBeAg-negative | 32 | 36.1 ± 4.9 | 32.6 ± 5.1* | 208.6 ± 35.2 | 77.5 ± 19.6* |
| HBeAg-positive | 25 | 46.4 ± 5.6 | 35.0 ± 2.4* | 384.4 ± 49.8 | 89.1 ± 21.4* |
| Responding group | 48 | 39.6 ± 5.4 | 32.9 ± 4.2* | 278.5 ± 43.1 | 76.1 ± 19.7* |
| Nonresponse group | 9 | 42.1 ± 5.9 | 36.2 ± 4.4* | 324.1 ± 33.7 | 91.2 ± 24.1* |
ALT, Alanine aminotransferase; IP-10, interferon-gamma inducible protein 10; CHB, Chronic hepatitis B;
*
Compared with pre-treatment serum ALT and IP-10 levels.